Table 2.
Best response according to each immunotherapy
| ORR (%) | DCR (%) | |
|---|---|---|
| Pembrolizumab | 51.6 | 67.7 |
| Nivolumab | 12.5 | 37.5 |
| Ipilimumab | 17.3 | 23.1 |
DCR disease control rate, ORR overall response rate
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.